Review

---

Primary liver cancer: clinical aspects, prognostic factors and predictive response to therapy

WCRJ 2015; 2 (3): e561

New entities in the treatment of hepatocellular carcinoma: HIV-positive and elderly patients

WCRJ 2015; 2 (3): e558

What to eat to reduce cancer risk?

WCRJ 2015; 2 (3): e555

Overview of FDA-approved anti cancer drugs used for targeted therapy

WCRJ 2015; 2 (3): e553

As dienogest effectively suppresses endometriosis, could it also reduce endometriosis-associated ovarian cancers? A further motivation for long-term medical treatment

WCRJ 2015; 2 (2): e526

Clinically relevant of Cytochrome P450 Family enzymes for drug-drug interaction in anticancer therapy

WCRJ 2015; 2 (2): e524

Role of traslational research in squamous cell carcinoma of the head and neck: is it possible to improve the therapeutic scenario?

WCRJ 2015; 2 (2): e520

Nutritional manipulation: epigenetic effect in cancer

WCRJ 2015; 2 (2): e518

Selected Pharmacogenetic panel test for toxicity prevention of drug-drug interactions between Highly Active Antiretroviral Therapy (HAART) and antiblastic chemotherapy

WCRJ 2015; 2 (1): e492

Hepatocellular carcinoma: an overview of clinico-pathological and molecular perspectives

WCRJ 2015; 2 (1): e485

• Newer
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• Older